Substrate-based approaches in ventricular tachycardia ablation

Joshua Hawson1, Ahmed Al-Kaisey1, Robert D Anderson1

  • 1Department of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Victoria, Australia.

Insights

Substrate-based ablation improves outcomes for ventricular tachycardia (VT) in structural heart disease when the clinical VT is difficult to map. This review covers strategies targeting abnormal electrograms, conduction channels, and slow conduction for better VT ablation results.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Catheter ablation is standard care for ventricular tachycardia (VT) in structural heart disease.
  • Mapping and ablating clinical VT can be challenging due to noninducibility, nonsustained rhythm, or hemodynamic intolerance.
  • Substrate-based ablation strategies have emerged to address these limitations and improve VT ablation outcomes.

Purpose of the Study:

  • To review contemporary substrate-based ablation strategies for ventricular tachycardia (VT).
  • To discuss the strengths and weaknesses of different substrate-based approaches.
  • To provide an overview of techniques used when direct VT mapping is not feasible.

Main Methods:

  • Review of current literature on substrate-based ablation for VT.
  • Categorization of strategies into three main approaches: targeting abnormal electrograms, anatomical conduction channels, and areas of slow/decremental conduction.
  • Discussion of techniques including "functional" substrate mapping.

Main Results:

  • Substrate-based ablation strategies have demonstrated improved outcomes compared to focused ablation of mapped VTs.
  • Various approaches exist, including linear ablation lines targeting ventricular scar.
  • Three primary categories of substrate ablation are identified and discussed.

Conclusions:

  • Substrate-based ablation is a valuable approach for managing ventricular tachycardia (VT) when clinical VT is not amenable to direct mapping.
  • Different strategies offer distinct advantages and disadvantages in treating VT associated with structural heart disease.
  • Further understanding and refinement of these techniques can optimize patient outcomes.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
147
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
104
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
65
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
965
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
130